Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

Autor: Kevin L. Winthrop, Kenneth Saag, Matthew D. Cascino, Jinglan Pei, Ani John, Angelika Jahreis, Tmirah Haselkorn, Daniel E. Furst, M. Abdulky, M. Abeles, H. Adelglass, A. Ahmed, J. Alloway, J. Alper, A. Anand, J. Anderson, M. Arora, A. Askari, S. Baca, D. Bacha, S. Bagheri, S. Ballou, R. Bennett, L. Bidula, H. Blumstein, M. Bognar, A. Bohan, C. Boniske, M. Borofsky, E. Box, A. Braun, T. Brennan, L. Brent, I. Cabalar, N. Carteron, K. Chaudhary, A. Chauhan, M. Cima, A. Cochinwala, H. Cohen, K. Colburn, D. Conaway, C. Danning, K. Dao, J. Dean, I. Diab, R. Diegel, R. Ditzian‐Kadanoff, J. Dowd, C. Dugowson, A. Eggebeen, H. El‐Kadi, H. Feinberg, M. Feinman, J. Feinstein, A. Fischer, B. Foad, M. Fondal, S. Fraser, A. Fraser, P. Freeman, M. Garber, A. Goldstein, S. Golombek, N. Greenstein, M. Greenwald, C. Hakim, J. Halla, D. Hallegua, K. Han, B. Harris, H. Hauptman, J. Hirsh, M. Hoffman, J. Huntwork, M. Husni, F. Hyer, R. Hymowitz, R. Jones, S. Kanagasegar, J. Kappes, R. Keating, G. Kelly, J. Kim, C. King, D. Klashman, C. Knee, K. Kolba, G. Krick, H. Krug, U. Kumar, S. Lakhanpal, T. Lang, S. Lauter, T. Lawrence Ford, W. Lee, Y. Lee, J. Leisen, J. Levine, R. Lidman, J. Lipstate, J. Malinak, R. Marcus, D. Martin, C. Mehta, G. Melton, S. Metyas, K. Miller, R. Moidel, C. Moore, J. Mossell, G. Munoz, F. Murphy, A. Nami, J. Nascimento, N. Neal, R. Neiman, C. Neuwelt, P. Nguyen, M. Niemer, K. Oelke, M. Oza, S. Pachaidee, S. Patel, S. Pegram, M. Penmetcha, J. Perkins, A. Perl, L. Peterson, R. Pittsley, K. Portnoff, D. Rahmani, N. Raja, W. Ratnoff, M. Rezaian, C. Rhea, D. Rice, D. Ridley, A. Rivadeneira, W. Rizzo, G. Roane, P. Rocca, M. Rosen, W. Saikali, M. Saitta, A. Sankoorikal, P. Saway, P. Schneider, S. Schwartzman, C. Scoville, W. Shergy, W Shiel, R. Shurmur, D. Sikes, A. Singhal, A. Snyder, S. Songcharoen, M. Sosenko, O. Soto Raices, N. Stahl, K. Stark, M. Strachan, A. Stupi, N. Sullivan, R. Sylvester, D. Tabechian, C. Tagoe, P. Taylor, S. Thakker, M. Thakor, N. Thakur, W. Tidmore, M. Toth, D. Trostle, J. Udell, M. Van de Stouwe, R. Venuturupalli, D. Weiss, K. Weselman, D. Winn, C. Yung, E. Zable, B. Zamiri

Publikováno v: Arthritis Care & Research

Objective To evaluate the long‐term safety of rituximab in an observational cohort of patients with rheumatoid arthritis (RA) who had an inadequate response to ≥1 anti–tumor necrosis factor therapy in the US (SUNSTONE [Study of the Safety of Ri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5502e0d966222c7403f4d23428329950
https://doi.org/10.1002/acr.23781

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Autor: McInnes IB; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. Electronic address: Iain.McInnes@glasgow.ac.uk., Mease PJ; Swedish Medical Center and University of Washington, Seattle, WA, USA., Kirkham B; Guy's and St Thomas' NHS Foundation Trust, London, UK., Kavanaugh A; Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, San Diego School of Medicine, San Diego, CA, USA., Ritchlin CT; Allergy/Immunology and Rheumatology Division, University of Rochester, Rochester, NY, USA., Rahman P; Memorial University, Newfoundland, NL, Canada., van der Heijde D; Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands., Landewé R; Amsterdam Rheumatology and Immunology Center, Amsterdam, and Atrium Medical Center, Heerlen, Netherlands., Conaghan PG; NIHR Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, UK., Gottlieb AB; Department of Dermatology, Tufts Medical Center, Boston, MA, USA., Richards H; Novartis Pharma, Basel, Switzerland., Pricop L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Ligozio G; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Patekar M; Novartis Healthcare, Hyderabad, India., Mpofu S; Novartis Pharma, Basel, Switzerland.

Publikováno v: Lancet (London, England) [Lancet] 2015 Sep 19; Vol. 386 (9999), pp. 1137-46. Date of Electronic Publication: 2015 Jun 28.